HanchorBio Launches HCB101 Mechanism Collaboration Study with the Institute of Tsinghua University, Hebei
Research collaboration will investigate innate and adaptive immune pathways underlying the antitumor activity of HCB101
[Taipei, Shanghai, San Francisco | May 5, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.
The collaboration is intended to deepen scientific understanding of the mechanisms and mode of action (MOA) underlying HCB101’s antitumor activity through focused in vivo studies spanning tumor immunity, immune cell function, antigen presentation, macrophage-mediated phagocytosis, downstream immune signaling, and hematologic biology. The work is expected to further strengthen the scientific foundation supporting the development of HCB101.
“Scientific depth matters,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “As HCB101 continues to advance, we want to build not only clinical evidence, but also a stronger mechanistic understanding of how this molecule engages tumor cells while avoiding effects on normal blood cells. We chose to work with the Institute of Tsinghua University, Hebei, because of its strong research capabilities and the scientific rigor needed to investigate these complex questions in relevant translational models.”
Dr. Liu added, “At HanchorBio, we believe differentiated medicines are built on differentiated science. This collaboration is intended to help define the biology with greater precision, from innate immune activation and antigen presentation to downstream adaptive immune responses. Deep translational work like this can sharpen biomarker strategy, strengthen the combination rationale, and further clarify the broader therapeutic potential of HCB101 to support smarter development decisions as we expand the program.”
Professor Yangxin Fu, a senior expert in tumor immunology, noted that HCB101 represents an innovative molecule of significant scientific value for translational research. Built upon a differentiated CD47-SIRPα-targeting mechanism, HCB101 is closely aligned with key research directions in tumor immunity and effector-cell biology and carries important exploratory value for scientific investigation.
A research representative from the Institute of Tsinghua University, Hebei, commented: “The Institute looks forward to working closely with HanchorBio through a systematic and standardized research program to further investigate the mechanism of HCB101 across relevant experimental models. The project will focus on key dimensions including tumor immune regulation, immune signaling, antigen presentation, and effector-cell function, with the goal of helping research teams better clarify the regulatory logic of the CD47-SIRPα signaling pathway and its impact on antitumor immune responses, thereby strengthening the theoretical foundation for basic research and clinical translation in this field.”
The collaboration reflects HanchorBio’s broader approach of integrating clinical development with rigorous translational research to support next-generation immunotherapy programs.
About HCB101
HCB101 is a rationally engineered SIRPα–IgG4 Fc fusion protein developed using HanchorBio’s FBDB™ platform to selectively block the CD47–SIRPα innate immune checkpoint while minimizing hematologic toxicity. Unlike earlier anti-CD47 approaches, HCB101 is designed to preserve macrophage-mediated antitumor activity while reducing red blood cell binding, a limitation that historically constrained development across the CD47 class. HCB101 is being evaluated across multiple clinical settings as both monotherapy and combination therapy.
About the Institute of Tsinghua University, Hebei
The Institute of Tsinghua University, Hebei, was established in 2002 as a public institution jointly established by the Hebei Provincial People’s Government and Tsinghua University. With its headquarters in Shijiazhuang and additional bases in Langfang and Gu’an, the Institute is positioned around the coordinated development strategy of the Beijing-Tianjin-Hebei region and the development of Xiong’an New Area.
The Institute focuses on building a world-class new-type research and development institution by leveraging Hebei’s regional, industrial, and market advantages together with Tsinghua University’s innovation resources and organizational strengths. Its key areas of focus include carbon neutrality, life and health, intelligent equipment and electronic information technology, digital economy, and industrial design. The Institute aims to establish a full-chain innovation model spanning technology research and development, proof of concept, pilot-scale maturation, incubation, and translation, with the goal of becoming an influential regional integrated innovation center in China.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.
漢康生技與河北清華發展研究院展開 HCB101 作用機制研究合作
此項合作將探討 HCB101 抗腫瘤活性背後所涉及的先天與適應性免疫途徑
漢康生技（TPEx：7827）為一家致力於開發次世代免疫療法、聚焦腫瘤與自體免疫疾病的全球臨床階段生技公司，今日宣布，與河北清華發展研究院展開合作，進一步解析 HCB101 的抗腫瘤作用機制與轉譯生物學。HCB101 為公司以 AI 輔助、經結構工程設計的 Fc 融合蛋白，靶向 CD47-SIRPα。
此次合作旨在聚焦於體內研究，深入了解 HCB101 抗腫瘤活性背後的作用機制（mechanism of action）與作用模式（mode of action），研究範圍涵蓋腫瘤免疫、免疫細胞功能、抗原呈現、巨噬細胞介導之吞噬作用、下游免疫訊號傳遞，以及血液學相關生物學。此項研究預期將進一步強化奠定 HCB101開發的科學基礎。
漢康生技創辦人、董事長暨執行長劉世高博士表示，深度的科學探討非常重要，隨著 HCB101 持續推進開發，漢康致力於建立的不只是臨床證據，亦包括更深入扎實的機制性理解，以釐清此分子如何在作用於腫瘤細胞的同時，仍能避免影響正常血球。漢康選擇與河北清華發展研究院合作，是因為其具備卓越的研究能力，以及在相關轉譯模型中探討這些複雜問題所需的科學嚴謹性。
劉博士進一步表示，漢康相信具差異化的藥物建立在具差異化的科學之上。此次合作旨在更精準地界定其生物學機制，從先天免疫活化與抗原呈現，到下游適應性免疫反應。這類深入的轉譯研究可望優化生物標記策略、強化聯合治療的科學依據，並進一步釐清 HCB101 更廣泛的治療潛力，支持漢康在擴展此項目時做出更精準的決策。
腫瘤免疫領域資深專家傅陽心教授指出，HCB101 是轉化研究領域極具科學價值的創新分子。該藥物依託差異化設計的 CD47-SIRPα 靶向作用機制，精準契合腫瘤免疫與效應細胞生物學領域的核心研究方向，具備重要的科研探索意義。
河北清華發展研究院相關科研負責人表示，研究院十分期待與漢康生技達成深度合作，依託系統化、規範化的研究方案，全面深挖 HCB101 在各類實驗模型中的作用機理。專案將圍繞腫瘤免疫調控、免疫訊號傳導、抗原呈遞機制及效應細胞功能等關鍵維度開展系統性研究，助力科研團隊進一步釐清 CD47-SIRPα 訊號通路的調控邏輯，清楚分析其對抗腫瘤免疫回應的影響機制，為相關領域基礎研究與臨床轉化應用築牢理論支撐。
此次合作也反映出漢康生技更廣泛的策略，即結合臨床開發與嚴謹的轉譯研究，以支持次世代免疫治療項目的推進。
關於 HCB101
HCB101 為漢康生技以 FBDB™ 平台理性設計開發之 SIRPα–IgG4 Fc 融合蛋白，旨在選擇性阻斷 CD47–SIRPα 先天免疫檢查點，同時降低血液學毒性。不同於早期的抗 CD47，HCB101 在保留巨噬細胞介導抗腫瘤活性的同時，降低對紅血球 CD47 的結合能力，以克服過去限制該療法發展的關鍵挑戰。
透過 AI 輔助結構建模，HCB101 對腫瘤細胞上的 CD47 具差異化結合特性，並維持對紅血球 CD47 的低親和力。其安全性、受體佔有率與藥理特性，皆有利於與既有腫瘤治療方案整合。目前 HCB101 正於胃癌、大腸直腸癌及頭頸癌等適應症持續進行劑量遞增與臨床二期擴展研究。
綜合上述特質，HCB101 已定位為具備差異化的先天免疫檢查點骨幹（Backbone），並具備橫跨實體腫瘤與血液腫瘤的廣泛潛力。
關於河北清華發展研究院
河北清華發展研究院成立於 2002 年，是河北省人民政府與清華大學共建的事業法人單位，設有石家莊總部和廊坊、固安兩個基地。研究院牢牢把握京津冀協同發展戰略和雄安新區建設的重大歷史機遇，對標對表世界一流新型研發機構建設，充分發揮河北區位、產業、市場優勢和清華大學創新資源與創新組織優勢，重點佈局碳中和、生命健康、智慧裝備與電子資訊技術、數位經濟、工業設計五大方向，構建從「科技研發—概念驗證—中試熟化—孵化轉化」的全鏈條科創範式，致力於打造全國有影響力的區域融合創新中心。
關於漢康生技
漢康生技（股票代碼：7827.TPEx）是一家全球臨床階段的生物技術公司，專注於腫瘤免疫學及自體免疫疾病領域，研發總部設於台北，並在上海及美國舊金山灣區設有運營辦公室。公司由一支在生物藥發現與全球開發方面擁有豐富成功經驗的資深團隊領導，致力於重塑癌症治療格局。漢康生技專有的Fc基礎設計生物藥平台能夠開發具有多種靶向模式的多功能生物藥，旨在激活先天性與適應性免疫通路，以突破當前抗PD-1/L1免疫療法的局限。該平台已在多個體內腫瘤動物模型中成功獲得概念驗證數據。通過差異化的分子研發策略與可規模化的CMC工藝開發，漢康生技正推進一系列創新生物藥管線，致力於解決尚未被滿足的重大醫療需求。